A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer

Autor: Otilia Dalesio, Guiseppe Giaccone, A.S.T. Planting, G. McVie, P. Helle, Anne Kirkpatrick, P. Drings

Publikováno v: Annals of Oncology. 7:139-144

Summary Background The treatment results of radiotherapy in stage III non-small-cell lung cancer are very poor. Several phase II studies showed that neoadjuvant chemotherapy followed by radiotherapy was feasible in this patient group and suggested th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6eb93c59eab2a6b8452db97e9a6cf6c
https://doi.org/10.1093/oxfordjournals.annonc.a010540

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group

Autor: Tarek Sahmoud, Karin Mattson, L. Tammilehto, J. van Pawel, Andrea Ardizzoni, K. J. Roozendaal, A.S.T. Planting, M. Schrijver, G. Giaccone, N. van Zandwijk, Anne Kirkpatrick, Ted A.W. Splinter, T. Sutedja, Pe Postmus, Paul Baas, C. van Pottelsberghe, M. van Glabbeke

Publikováno v: European Journal of Cancer, 33, 2211-2215. Pergamon
European Journal of Cancer, 33(13), 2211-2215. Elsevier Ltd.
European Journal of Cancer, 33(13), 2211-2215. ELSEVIER SCI LTD
Sahmoud, T, Postmus, P E, van Pottelsberghe, C, Mattson, K, Tammilehto, L, Splinter, T A W, Planting, A S T, Sutedja, G, van Pawel, J, van Zandwijk, N, Baas, P & Roozendaal, K J 1997, ' Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group ', European Journal of Cancer, vol. 33, pp. 2211-2215 . https://doi.org/10.1016/S0959-8049(97)00183-4

Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mg/m(2) on days

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e4fa9a8a3bd6cc3be1125ee25c9b38
https://research.vumc.nl/en/publications/b694fdb6-c566-4e28-baa3-505d3f8ebac7

392 Randomized Phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer

Autor: A. de Graeff, A.S.T. Planting, P.H.M. de Mulder, H.E.R. Verdonk, W. Oster, G. Catimel, J.B. Vermorken

Publikováno v: European Journal of Cancer. 31:S85-S86

High dose single agent cisplatin (C) regimens yield high response rates in advanced head and neck cancer (HNC) but nephro-, neuro- and ototoxicity preclude further dose escalation. In weekly C regimens bone marrow toxicity causes frequent treatment d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6027fa2500a6c402697b1ef66e188f81
https://doi.org/10.1016/0959-8049(95)95645-m

Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial

Autor: J. Festen, F.J. Palmen, C. Vendrik, A.S.T. Planting, Pieter E. Postmus, T.A.W. Splinter, K. J. Roozendaal, Jg Mcvie, Anne Kirkpatrick, E. Quoix, Otilia Dalesio, D.N. Carney, J. Burghouts

Publikováno v: Cancer treatment reviews. 15

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c709f351028e203d593c6f68287e8ce
https://pubmed.ncbi.nlm.nih.gov/2841023

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.